Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast
Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has scheduled its third quarter 2024 financial results announcement for Tuesday, November 12, 2024, after market close. The company will host a conference call and webcast at 4:30 p.m. ET on the same day. Investors can access the live webcast through the company's investor relations website, with a replay available for at least 30 days after the event.
Voyager Therapeutics (Nasdaq: VYGR), un'azienda biofarmaceutica focalizzata sulle medicine neurogenetiche, ha programmato l'annuncio dei risultati finanziari del terzo trimestre 2024 per martedì 12 novembre 2024, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica e una diretta web alle 16:30 ET dello stesso giorno. Gli investitori possono accedere alla diretta web attraverso il sito delle relazioni con gli investitori dell'azienda, con una registrazione disponibile per almeno 30 giorni dopo l'evento.
Voyager Therapeutics (Nasdaq: VYGR), una empresa biotecnológica centrada en medicamentos neurogenéticos, ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 para el martes 12 de noviembre de 2024, después del cierre del mercado. La compañía llevará a cabo una llamada de conferencia y una transmisión por web a las 4:30 p.m. ET el mismo día. Los inversionistas pueden acceder a la transmisión en vivo a través del sitio web de relaciones con inversionistas de la empresa, con una repetición disponible durante al menos 30 días después del evento.
보이저 치료제 (Nasdaq: VYGR), 신경 유전 의약품에 중점을 둔 생명공학 기업은 2024년 3분기 재무 결과 발표를 2024년 11월 12일 화요일, 시장 마감 후로 예정하고 있습니다. 회사는 같은 날 오후 4시 30분 ET에 컨퍼런스 콜과 웹캐스트를 개최할 예정입니다. 투자자들은 회사의 투자자 관계 웹사이트를 통해 실시간 웹캐스트에 접속할 수 있으며, 이벤트 후 최소 30일 동안 다시 볼 수 있습니다.
Voyager Therapeutics (Nasdaq: VYGR), une entreprise biopharmaceutique axée sur les médicaments neurogénétiques, a prévu l'annonce de ses résultats financiers pour le troisième trimestre 2024 le mardi 12 novembre 2024, après la fermeture du marché. L'entreprise tiendra une conférence téléphonique et un webinaire le même jour à 16h30 ET. Les investisseurs peuvent accéder à la diffusion en direct via le site Web des relations investisseurs de l'entreprise, avec une rediffusion disponible pendant au moins 30 jours après l'événement.
Voyager Therapeutics (Nasdaq: VYGR), ein biopharmazeutisches Unternehmen, das sich auf neurogenetische Arzneimittel konzentriert, hat die Bekanntgabe seiner finanziellen Ergebnisse für das dritte Quartal 2024 für Dienstag, den 12. November 2024, nach Börsenschluss terminiert. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten. Investoren können über die Investor-Relations-Website des Unternehmens auf den Live-Webcast zugreifen, wobei eine Wiederholung mindestens 30 Tage nach der Veranstaltung verfügbar sein wird.
- None.
- None.
LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report third quarter 2024 financial and operating results after market close on Tuesday, November 12, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET.
A live webcast of the call will be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.
About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.
Contacts
Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Mike Hencke, mhencke@kendallir.com
Media: Brooke Shenkin, brooke@scientpr.com
FAQ
When will Voyager Therapeutics (VYGR) report Q3 2024 earnings?
What time is Voyager Therapeutics (VYGR) Q3 2024 earnings call?
How can I access Voyager Therapeutics (VYGR) Q3 2024 earnings call?
